Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

208 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Phase I Trial of Brentuximab Vedotin Plus Cyclosporine in Relapsed/Refractory Hodgkin Lymphoma.
Thiruvengadam SK, Mei MG, Chen L, Puverel S, Chen R, Popplewell LL, Nikolaenko L, Peters L, Armenian S, Kwak LW, Rosen ST, Forman SJ, Herrera AF. Thiruvengadam SK, et al. Among authors: kwak lw. Clin Lymphoma Myeloma Leuk. 2024 Oct;24(10):724-731.e1. doi: 10.1016/j.clml.2024.05.017. Epub 2024 Jun 15. Clin Lymphoma Myeloma Leuk. 2024. PMID: 39043499 Clinical Trial.
Brentuximab vedotin plus nivolumab after autologous haematopoietic stem-cell transplantation for adult patients with high-risk classic Hodgkin lymphoma: a multicentre, phase 2 trial.
Herrera AF, Chen L, Nieto Y, Holmberg L, Johnston P, Mei M, Popplewell L, Armenian S, Cao T, Farol L, Sahebi F, Spielberger R, Chen R, Nademanee A, Puverel S, Nwangwu M, Lee P, Song J, Skarbnik A, Kennedy N, Peters L, Rosen ST, Kwak LW, Forman SJ, Feldman T. Herrera AF, et al. Among authors: kwak lw. Lancet Haematol. 2023 Jan;10(1):e14-e23. doi: 10.1016/S2352-3026(22)00318-0. Epub 2022 Nov 17. Lancet Haematol. 2023. PMID: 36403579 Clinical Trial.
Pembrolizumab plus vorinostat induces responses in patients with Hodgkin lymphoma refractory to prior PD-1 blockade.
Mei M, Chen L, Godfrey J, Song J, Egelston C, Puverel S, Budde LE, Armenian S, Nikolaenko L, Nwangwu M, Guo W, Gao L, Lee P, Chen R, Daniels S, Kennedy N, Peters L, Zain J, Rosen S, Forman S, Popplewell L, Kwak L, Herrera AF. Mei M, et al. Blood. 2023 Oct 19;142(16):1359-1370. doi: 10.1182/blood.2023020485. Blood. 2023. PMID: 37339586 Free PMC article.
Results from a phase I trial of pembrolizumab plus vorinostat in relapsed/refractory B-cell non-Hodgkin lymphoma.
Godfrey J, Mei M, Chen L, Song JY, Bedell V, Budde E, Armenian S, Puverel S, Nikolaenko L, Chen R, Daniels S, Kennedy N, Peters L, Rosen ST, Forman SJ, Popplewell LL, Kwak LW, Herrera AF. Godfrey J, et al. Among authors: kwak lw. Haematologica. 2024 Feb 1;109(2):533-542. doi: 10.3324/haematol.2023.283002. Haematologica. 2024. PMID: 37470137 Free PMC article. Clinical Trial.
Brentuximab Vedotin Plus Ibrutinib in Relapsed and Refractory Hodgkin Lymphoma.
Mei M, Tsai NC, Palmer J, Armenian S, Chen R, Rosen S, Forman S, Popplewell L, Kwak L, Martin P, Maddocks K, Bond D, Herrera AF. Mei M, et al. Clin Lymphoma Myeloma Leuk. 2024 Aug;24(8):537-542. doi: 10.1016/j.clml.2024.03.013. Epub 2024 Apr 10. Clin Lymphoma Myeloma Leuk. 2024. PMID: 38693037 Clinical Trial.
Brentuximab vedotin plus cyclophosphamide, doxorubicin, etoposide, and prednisone followed by brentuximab vedotin consolidation in CD30-positive peripheral T-cell lymphomas: a multicentre, single-arm, phase 2 study.
Herrera AF, Zain J, Savage KJ, Feldman T, Brammer JE, Chen L, Puverel S, Popplewell L, Budde LE, Mei M, Hosing C, Nair R, Leslie L, Daniels S, Peters L, Forman S, Rosen S, Kwak L, Iyer SP. Herrera AF, et al. Lancet Haematol. 2024 Sep;11(9):e671-e681. doi: 10.1016/S2352-3026(24)00171-6. Epub 2024 Jul 24. Lancet Haematol. 2024. PMID: 39067464 Clinical Trial.
Oligo-PROTAC strategy for cell-selective and targeted degradation of activated STAT3.
Hall J, Zhang Z, Wang D, Bhattacharya S, Alcantara M, Liang Y, Swiderski P, Forman S, Kwak L, Vaidehi N, Kortylewski M. Hall J, et al. bioRxiv [Preprint]. 2023 Aug 3:2023.08.01.551552. doi: 10.1101/2023.08.01.551552. bioRxiv. 2023. Update in: Mol Ther Nucleic Acids. 2024 Feb 05;35(1):102137. doi: 10.1016/j.omtn.2024.102137 PMID: 37577590 Free PMC article. Updated. Preprint.
208 results